Alpine Immune Sciences (NASDAQ:ALPN) posted its earnings results on Tuesday. The biotechnology company reported ($0.64) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.68) by $0.04, Fidelity Earnings reports. The firm had revenue of $0.57 million for the quarter, compared to analyst estimates of $0.25 million.
ALPN opened at $3.50 on Wednesday. The business’s 50-day moving average price is $4.24. The company has a debt-to-equity ratio of 0.03, a current ratio of 7.33 and a quick ratio of 7.33. Alpine Immune Sciences has a one year low of $3.41 and a one year high of $8.24. The firm has a market capitalization of $65.00 million, a PE ratio of -1.33 and a beta of 1.88.
A number of research firms have recently commented on ALPN. Zacks Investment Research cut Alpine Immune Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, July 10th. ValuEngine upgraded Alpine Immune Sciences from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Alpine Immune Sciences currently has an average rating of “Buy” and a consensus price target of $10.69.
In other news, VP James Paul Rickey bought 10,000 shares of the business’s stock in a transaction dated Thursday, May 30th. The shares were acquired at an average price of $4.95 per share, for a total transaction of $49,500.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 75.10% of the stock is currently owned by insiders.
About Alpine Immune Sciences
Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer.
Read More: Percentage Gainers
Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.